Surprisingly few new parents enlist in study to have baby's genome sequenced
By Jocelyn Kaiser,
Science Magazine
| 10. 19. 2016
One of the first studies to explore the idea of routinely sequencing the genes of newborns to help guide their health care has run into an unexpected road bump: Few parents approached are interested in having their baby’s genome profiled.
When Robert Green, a geneticist at the Harvard University–affiliated Brigham and Women’s Hospital in Boston, and co-workers began planning to sequence babies about 4 years ago, they surveyed more than 500 parents of healthy newborns. Nearly half declared they would be “very” or “extremely” interested and another 37% said “somewhat.” But since their actual BabySeq Project began last year in May, only about 7% of more than 2400 couples approached so far have agreed to participate, says Green, who co-leads BabySeq with Alan Beggs of Boston Children's Hospital. That “very surprising” figure is the same both for parents of very sick infants and those with healthy babies, he adds.
BabySeq is one of four projects funded by the National Institutes of Health (NIH) 3 years ago to probe the risks and benefits of sequencing newborns’ DNA and compare the results to conventional newborn...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...